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It is known that a high incidence of hepatocellular carcinoma in rat liver can be induced by such azo dye carcinogens a  3'-methyl-4-dimethyl- 
aminoazobenzene (3'-MeDAB). Mammalian S-adenosylmethionine (AdoMet) synthetase exists as two isozymes, non-hepatic-type and liver-type 
enzymes, which are the products of two different genes. We have examined the expression oftwo AdoMet synthetase isozyme proteins and mRNAs 
in rat hepatomas induced by 3'-Me-DAB. The levels of non-hepatic-type enzyme protein and mRNA are clearly induced by 3'-Me-DAB feeding. 
On the other hand, the levels of liver-type nzyme protein and mRNA are nearly the same or slightly decreased during hepatocarcinogenesis. These 
results indicate that the expression of the non-hepatic-type isozyme gene is obviously influenced with the progression of carcinogenesis and that 
the non-hepatic-type isozyme is useful as a oncodevelopmental m rker in the liver. 
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1. INTRODUCTION 
S-Adenosylmethionine (AdoMet) synthetase (ATP:L- 
methionine S-adenosyltransferase (EC 2.5.1.6)), which 
Cantoni [1] first reported, is the enzyme responsible for 
the formation of AdoMet from methionine and ATE 
AdoMet is an important methyl donor in most trans- 
methylation reactions and is also the propylamino 
donor in the biosynthesis of polyamines. 
In mammals, AdoMet synthetase xists as two 
isozymes, liver-type and non-hepatic-type enzymes, re- 
spectively. The liver-type isozyme is confined to the 
liver, whereas the non-hepatic-type isozyme is widely 
distributed in various tissues examined [2-6]. We have 
recently reported that the non-hepatic-type isozyme 
mRNA predominantly exists in fetal human liver and 
is replaced by the liver-type isozyme mRNA during 
development [7]. Therefore, it seems of particular inter- 
est to investigate whether the expression of non-hepatic- 
type isozyme during the hepatocarcinogenic process is 
a feature of cell proliferation and whether or not the 
non-hepatic-type enzyme is useful as a tumor marker 
for the detection of oncodevelopmental changes into 
hepatocellular carcinoma. 
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In the present study, we have investigated the expres- 
sion of the two AdoMet synthetase isozyme genes in the 
livers of rats treated with 3'-methyl-4-dimethylami- 
noazobenzene (3'-Me-DAB) as an experimental model 
for hepatocarcinogenesis. It is known that a high inci- 
dence of hepatocellular carcinoma in rat liver can be 
induced by such azo dye carcinogens as 3'-Me-DAB 
[8 12]. 
2. MATERIALS AND METHODS 
2.1. Materials 
[c~-32p]dCTP, rotein A-TSK gel, Hybond-C and Hybond-N were 
obtained from Amersham. The random-primed DNA labeling kit was 
from Takara (Kyoto, Japan). Alkaline phosphatase-conjugated goat 
anti-rabbit IgG was from Vector Laboratories. 5-Bromo-4-chloro-3- 
indolyl phosphate (BCIP) and nitro blue tetrazolium chloride (NBT) 
were from Promega. Keyhole limpet hemocyanin was from Calbio- 
chem. All other chemicals and reagents were of analytical grade and 
obtained from commercial suppliers. 
2.2. Animals 
Male Sprague Dawley rats 8-9 weeks of age were grown on a diet 
containing 0.06% 3'-Me-DAB and water freely, and were sacrificed on 
0, 9, and 19 weeks. 
2.3. Northern blot analysis 
Total RNA was prepared by a single-step guanidium thiocyanate/ 
phenol/chloroform extraction procedure described by Chomczynski et
al. [13]. RNA (10/lg per lane) was denatured in glyoxal and dimeth- 
ylsulfoxide and separated on a 1.0% agarose gel as described by Tho- 
mas [14], then transferred tonylon membranes. Prehybridization a d 
hybridization of the membranes were performed as described [4]. 
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EcoRI inserts of rat non-hepatic-type [4] and liver-type AdoMet syn- 
thetase cDNA [15] probes were labeled by the random-primed DNA 
labeling kit and [~x-32p]dCTE RNA gels were stained with ethidium 
bromide and examined toascertain that equivalent amounts of RNA 
were analyzed. Filters were washed twice for 15 min each in 2 × SSC 
(1 x SSC: 0.15 M NaCI, 0.015 M Na-citrate, pH 7.0), 0.1% SDS at 
room temperature, then at 65°C for 2 x 15 min in 0.3 x SSC, 0.1% 
SDS. The final wash was for 1 h at 65°C in 0.1 x SSC, 0.1% SDS. 
Autoradiography was performed at -80°C for 14 days. 
2.4. Western blot analysis" 
Antibody against rat liver-type AdoMet synthetase was prepared 
[16] and further purified by affinity chromatography as described in
[17]. A hexadecapeptide with a sequence of NGQLNGFHEAF- 
IEEGT (amino acid residues 2 17) near the NH 2 terminal segment of
rat non-hepatic-type AdoMet synthetase [4]was selected as an immu- 
nogen based on its low homology with liver-type AdoMet synthetase 
[15]. The peptide was synthesized by using an Applied Biosystems 
model 430A peptide synthesizer and the product was confirmed by 
analytical HPLC and automated amino acid sequencing (Applied Bi- 
osystems model 470A gas phase sequencer) and coupled to keyhole 
limpet hemocyanin with glutaraldehyde [18]. The antibody was raised 
in rabbit and purified from the antiserum by the protein A-TSK gel. 
Rats were killed by decapitation and their tissues were removed. 
Individual tissues were homogenized with a glass-Teflon homogenizer 
in 10 Vols. of 0.25 M sucrose containing 3.3 mM MgC12 and centri- 
fuged at 3,000 × g for 10 min at 4°C to obtain postnuclear extracts or 
105,000 ×g for 60 min to prepare the cytosolic fractions. The samples 
were separated by SDS-PAGE according to Laemmli [19] with 10% 
acrylamide. Bovine serum albumin (67 kDa) and ovalbumin (43 kDa) 
were used as markers. Immunoblotting experiments were carried out 
as described in [20] except that the alkaline phosphatase-conjugated 
anti-rabbit IgG was used. The immunoreaction was visualized by 
staining with the BCIP/NBT detection kit. Protein concentration was 
determined by Bradford [21]. 
3. RESULTS AND DISCUSSION 
It is difficult to accurately discriminate between the 
non-hepatic-type and liver-type AdoMet  synthetases in
cell extracts by determining the enzyme activities. 
Therefore, we have prepared the antibodies against each 
isozyme as described in section 2. To examine the spec- 
ificity of each antibody against AdoMet synthetase 
isozymes, Western blot analysis was performed (Fig. 1). 
When the cytosolic extracts from various rat tissues 
were immunoblotted,  the anti-rat liver-type AdoMet  
synthetase antibody specifically reacted with a 48-kDa 
band only in rat liver extract (Fig. 1A), but not in the 
extracts of rat brain, testis, and spleen. In contrast, the 
anti-rat non-hepatic-type AdoMet  synthetase antibody 
also specifically detected the band of 48-kDa in rat 
brain, testis, and spleen extracts (Fig. 1B). Antibodies 
specific for each of the liver-type and non-hepatic-type 
enzymes reacted with the same molecular size, but dis- 
tinct polypeptide species of 48 kDa, respectively. These 
results clearly show that these antibodies are highly 
specific. 
Using these antibodies, we investigated the expres- 
sion of the two AdoMet synthetase isozyme proteins in 
the liver extracts treated with 3' -Me-DAB as described 
in section 2 (Fig. 2). In the Western blot analysis hown 
in Fig. 2, the expression of the non-hepatic-type enzyme 
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Fig. 1. Immunoblots ofS-adenosylmethionine sy thetase isozymes in
various rat tissues. Cytosolic extracts of rat tissues (20/1g/lane) were 
subjected to SDS-PAGE followed by immunoblotting. (A) Anti-rat 
liver-type AdoMet synthetase antibody; (B) anti-rat non-hepatic-type 
AdoMet syntbetase antibody; lane 1, spleen; lane 2, testis; lane 3, 
brain; lane 4, liver. Molecular mass markers used are bovine serum 
albumin (67 kDa) and ovalbumin (43 kDa). 
protein (48 kDa) was clearly induced at 9 weeks after 
the onset of 3' -Me-DAB feeding and raised further at 
19 weeks (Fig. 2B). On the other hand, the levels of 
liver-type isozyme protein were nearly the same during 
the period (Fig. 2A). These results have shown that the 
non-hepatic-type AdoMet synthetase protein is signifi- 
cantly induced in the liver by the 3' -Me-DAB feeding. 
At 19 weeks after the onset of 3' -Me-DAB feeding, a 
hepatocarcinoma w s induced with a nearly 100% inci- 
dence. 
To examine if the expression of the non-hepatic-type 
AdoMet synthetase gene was associated with the induc- 
tion of its enzyme protein, we have performed a North- 
ern blot analysis using both rat non-hepatic-type and 
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Fig. 2. Immunoblots ofS-adenosylmethionine sy thetase isozymes in
liver extracts of rats treated by 3'-Me-DAB feeding. Rat liver postnu- 
clear extracts (50 ¢tg/lane) at various times after the onset of 3'-Me- 
DAB feeding were subjected toSDS-PAGE followed by immunoblot- 
ting. (A) Anti-rat liver-type AdoMet synthetase antibody; (B) anti-rat 
non-hepatic-type AdoMet synthetase; lane 1, normal control; lane 2, 
9 weeks; lane 3, 19 weeks. Molecular mass markers used are bovine 
serum albumin (67 kDa) and ovalbumin (43 kDa). 
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Fig. 3. RNA blots of S-adenosylmethionine synthetase isozymes in 
liver extracts of rats treated by 3"-Me-DAB feeding. Total RNAs (10 
/1g/lane) from normal control (lane 1), at 9 weeks (lane 2), and at 19 
weeks (lane 3) after the onset of 3'-Me-DAB feeding were subjected 
to RNA blot analysis using the EcoRI inserts of cDNAs for rat 
liver-type AdoMet synthetase (A) and rat non-hepatic-type AdoMet 
synthetase (B). Molecular size markers used are 28 S and 18 S rRNAs. 
liver-type AdoMet synthetase cDNAs as probes (Fig. 
3). When hybridization is performed at high stringency, 
we can discriminate between the two isozyme mRNAs 
as described in [4]. The levels of the liver-type AdoMet 
synthetase mRNA (3.4 kb) ar~taearly the same during 
the progress of carcinogenesis (Fig. 3A). This result is 
consistent with Mato's group's findings that no signifi- 
cant differences in the liver-type AdoMet synthetase 
mRNA levels were observed when samples obtained 
from biopsies of patients with alcoholic cirrhosis and 
hepatocellular carcinoma were compared with the cor- 
responding controls [22]. In their study, however, the 
levels of non-hepatic-type isozyme mRNA was not ex- 
amined. Therefore, we have investigated the expression 
of non-hepatic-type isozyme mRNA. Contrary to the 
liver-type isozyme, the non-hepatic-type AdoMet syn- 
thetase cDNA probe detected a very faint band of 3.4- 
kb mRNA in the normal liver (0 week), and then its 
expression was induced strikingly at 9 and 19 weeks 
after administration of 3"-Me-DAB. The amount of 
RNA loaded was approximately equal as demonstrated 
by the ethidium bromide-stained 28 S and 18 S ribo- 
somal RNA bands (data not shown). The expression of 
the non-hepatic-type AdoMet synthetase mRNA corre- 
lates quite well with the levels of this enzyme protein. 
The above observation has clearly shown that the ex- 
pression of non-hepatic-type AdoMet synthetase gene 
is induced by 3'-Me-DAB treatment. In this respect, the 
relationship between the expression of non-hepatic-type 
AdoMet synthetase and the progression of hepatomas 
seems to be correlated. 
Mato's group has reported that AdoMet synthetase 
activity is greatly reduced in human cirrhosis, however, 
the cirrhotic liver presents normal levels of liver-type 
AdoMet synthetase mRNA compared with the controls 
[22,23]. We have recently reported that the non-hepatic- 
type AdoMet synthetase protein and mRNA were pre- 
dominantly expressed in the fetal liver [7,24]. These 
findings strongly suggest hat the induction of non-he- 
patic-type AdoMet synthetase may be one of the cancer- 
ous signal in the liver. The physiological significance of 
this observation remains to be clarified. The mecha- 
nisms underlying the control of non-hepatic-type 
AdoMet synthetase may be important o understand 
the progression of hepatocarcinogenesis. We are at 
present continuing work to investigate whether or not 
any differences exist between the fetal and hepatoma 
tissues. 
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